The purchase price for the firm is an initial $140 million, with an additional $25 million potentially following by 2016, depending on milestones. The deal, which has already closed, will “significantly expand” the business opportunities for Bard’s surgical specialties unit, the firm said.
Neomend has only one product at this time, the Progel air leak sealant, which is the only FDA-approved intraoperative sealant...